Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 Pharma Stocks to Sell in March Before They Crash & Burn

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day

Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study

Stocks making the biggest moves midday: Southwest, Oracle, 3M, New York Community Bancorp and more

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

Analysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)

ACADIA Pharmaceuticals Maintains Buy Rating Despite Price Target Adjustment

Acadia (NASDAQ:ACAD) Plunges as Pimavanserin Disappoints in Phase 3 Trial